Attached

July 24, 2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, Corporate Relationship Department Plot No. C/1, G Block, Phiroze Jeejeebhoy Towers Bandra Kurla Complex, Bandra (E) Dalal Street Mumbai – 400 051 Mumbai – 400 001 Symbol: LALPATHLAB Scrip Code: 539524 Sub: Earnings Presentation on Un-audited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2026 Dear Sir/Madam, Please find attached a copy of Company's Earnings Presentation, which the Company proposes to share with Analysts / Investors with respect to its Un-Audited Financial Results (Standalone and Consolidated) for the Quarter ended June 30, 2026, as approved by the Board of Directors in their meeting held on July 24, 2026. We request you to please take the same on record. Thanking You, Yours Faithfully, For Dr. Lal PathLabs Limited Vinay Gujral Company Secretary & Compliance Officer Encl.: As above Classification: Internal Results Presentation Q1 FY2027 Disclaimer By attending the meeting / telephonic call where this presentation is made, or by reading the presentation materials, you agree to be bound by the following limitations: The information in this presentation has been prepared by Dr Lal PathLabs Limited (the “Company”) for use in presentations by the Company at analyst and investor meetings and does not constitute a recommendation regarding the securities of the Company. No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. Neither the Company nor any of its advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. The information set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially. Neither the Company nor any of its advisors or representatives is under any obligation to update or keep current the information contained herein. The information communicated in this presentation contains certain statements that are or may be forward looking. These statements typically contain words such as "will", "expects" and "anticipates" and words of similar import. By their nature forward looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. Any investment in securities issued by the Company will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, readers should not unduly rely on these forward-looking statements. The Company, its advisors and representatives assume no responsibility to update forward-looking statements or to adapt them to future events or developments. This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus under the (Indian) Companies Act, 2013 and will not be registered with any registrar of companies. Furthermore, this presentation is not and should not be construed as an offer or a solicitation of an offer to buy securities for sale in the India. This presentation and the information contained herein does not constitute or form part of any offer for sale or subscription of or solicitation or invitation of any offer to buy or subscribe for any securities of the Company, nor should it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered, sold or delivered within the United States or to U.S. persons absent from registration under or an applicable exemption from the registration requirements of the United States securities laws. This presentation and the information contained herein is being furnished to you solely for your information and may not be reproduced or redistributed to any other person, in whole or in part. In particular, neither the information contained in this presentation, nor any copy hereof may be, directly or indirectly, taken or transmitted into or distributed in the U.S., Canada, Australia, Japan or any other jurisdiction which prohibits the same except in compliance with applicable securities laws. Any failure to comply with this restriction may constitute a violation of the United States or other national securities laws. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted. By reviewing this presentation, you are deemed to have represented and agreed that you and any person you represent are either (a) a qualified institutional buyer (within the meaning of Regulation 144A under the Securities Act) or (b) not a U.S. person (as defined in Regulation S under the Securities Act) and are outside of the United States and not acting for the account or benefit of a U.S. person. Table of Contents DLPL - At a Glance 4 Q1 FY27 Performance Overview 5 Financials 6 Key Performance Highlights 7 Management Commentary 9 Shareholding 14 Corporate Overview 16 Contact Us 28 DISCLAIMER:Thispresentationmaycontain ‘forward-looking’statements atplaces.TheCompany’sbusinessoperationsremain subjecttoundeterminedcontingenciesandrisks.Dr. LalPathLabs Limitedwould notbeliableforanyactionundertakenbasedonsuch‘forward-looking’statementsanddoesnotcommittorevising/ updatingthempublicly. Dr. Lal PathLabs – At a Glance 75+ years of India’s 7,700 + 141 Mn 53 NABL & experience Leading & patients 2 CAP in the field Trusted serviced in accredited of Diagnostics last 5 years Labs Patient Service Centers(PSC’s) diagnostics Company 4,800 Pathology, Radiology tests & Panels; Comprehensive Test menu 12% 44% 280% AA+ * Stable FY26 Revenue ROCE Dividend for Credit Growth Excl. Cash & FY25-26 Rating# Investments Labs; Geographically spread-out network As on March 31,2026 * Adjusted for Bonus Issue 4 # Issued by Care Ratings Ltd. Q1 FY27 Performance Overview Q1 FY27 Q1 FY26 Gr % Revenue 798 670 (Rs. Cr.) 19.1% EBITDA 247 192 (Rs. Cr.) 28.7% PAT (Rs. Cr.) 170 134 27.2% Patients 8.2 7.6 8.2% (Mn) Samples 25.9 23.4 10.7% (Mn) SwasthFitTM Contribution 27% 27% - Financials Reported Results (Rs. Cr.) Q1 FY27 Q1 FY26 Gr % FY26 Revenue 798 670 19.1% 2,763 Material consumed 152 129 535 Employee benefit Expenses 133 124 533 Fees to collection centres 116 96 402 Other Expenses 150 129 540 EBITDA 247 192 28.7% 752 Margins 31.0% 28.7% 27.2% Other Income 32 28 101 Depreciation Cost 44 35 162 Finance Cost 6 5 23 PBT 229 181 26.3% 669 Margins 28.7% 27.0% 24.2% Income Tax 58 47 159 PAT 170 134 27.2% 510 Margins 21.4% 20.0% 18.4% EPS(Basic) 10.1 7.9 27.8% 30.2 Figures for the current quarter and the corresponding period last year have been reclassified and regrouped for better operational clarity and comparability. 6 Financial results of the Company are best monitored on a year-to-datebasis, as there is a certain level of seasonality in business and specific quarter performance may be influenced by certain occurrences in thatquarter. Key Performance Highlights- Q1 FY 27 Strong Revenue Growth Trajectory ➢ Highest quarterly Revenue growth in last 4 years ➢ Volume led Revenue growth driving strong performance for the quarter : • 10.7% YoY sample volume growth • 8.2% patient volume growth Key Pillars for growth • Scientific Leadership • Patient Experience • Operational Excellence Operating highlights No. of Clinical Laboratories No. of PSCs No. of PUPs +35 +2,625 +2,997 298 312 7,727 [Showing first 8,000 characters — download PDF for full document]